KALA BIO, Inc. (NASDAQ:KALA) Sees Large Drop in Short Interest

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 21,500 shares, a decline of 18.3% from the November 30th total of 26,300 shares. Based on an average trading volume of 26,200 shares, the short-interest ratio is currently 0.8 days. Currently, 0.6% of the shares of the company are short sold.

KALA BIO Stock Performance

Shares of KALA stock traded down $0.11 during trading hours on Monday, reaching $6.87. 34,421 shares of the company’s stock were exchanged, compared to its average volume of 77,617. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $9.25. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. The stock has a market capitalization of $31.67 million, a P/E ratio of -0.55 and a beta of -2.15. The business has a fifty day moving average price of $6.56 and a 200-day moving average price of $6.23.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. Analysts predict that KALA BIO will post -10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a research report on Friday, November 15th.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th largest position. SR One Capital Management LP owned about 15.76% of KALA BIO as of its most recent SEC filing. Institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.